title: [Clinical and echocardiographic evaluation of the effects of atrial defibrillation in patients with idiopathic cardiomyopathy].
abstract: To elucidate the effects of atrial defibrillation in patients with idiopathic cardiomyopathy, we clinically and echocardiographically assessed 6 patients with hypertrophic cardiomyopathy (HCM) and 7 patients with dilated cardiomyopathy (DCM). Their mean age was 57 +/- 14 years and the mean duration of their atrial fibrillation (Af) was 47 +/- 29 days. There were no differences in age and the duration of Af between the HCM and DCM groups. We assessed the effects of defibrillation on the NYHA functional classification, heart rate (HR), systolic blood pressure (S-BP), M-mode echocardiographic data (LVDd, LVDs, %FS, LAD) and transmitral pulsed Doppler echocardiographic findings (peak velocity, time-velocity integral of rapid and atrial filling waves). These indices were obtained before and 52 +/- 22 days after defibrillation, and were compared with each other. 1. HR decreased (HCM: 87 +/- 16-->58 +/- 7/min, DCM: 93 +/- 19-->70 +/- 14/min) and total left ventricular filling increased (HCM: 6 +/- 1-->11 +/- 4 cm, DCM: 6 +/- 1-->10 +/- 2 cm) after defibrillation, and the increment of %FS (HCM: 36 +/- 6-->41 +/- 6%, DCM: 16 +/- 6-->25 +/- 11%) was observed. Four of 6 HCM patients and 5 of 7 DCM patients also improved with regard to the NYHA classification. 2. After defibrillation, LVDd increased in HCM (42 +/- 4-->47 +/- 4 mm), but not in DCM. However, LVDs decreased in DCM (52 +/- 9-->44 +/- 12 mm), but not in HCM. We concluded that atrial defibrillation had a beneficial effect on the recovery of the left ventricular function both in HCM and DCM due to the reduction in HR and increase in left ventricular filling. The mode of LV functional improvement after defibrillation varied depending on the state of patient's basal pathophysiology .
authors.affiliation: First Department of Internal Medicine, Kobe University School of Medicine.
authors.forename: J
authors.initials: J
authors.lastname: Shite
authors.forename: Y
authors.initials: Y
authors.lastname: Yokota
authors.forename: M
authors.initials: M
authors.lastname: Nakatani
authors.forename: Y
authors.initials: Y
authors.lastname: Takeuchi
authors.forename: Y
authors.initials: Y
authors.lastname: Tsumura
authors.forename: H
authors.initials: H
authors.lastname: Kawai
authors.forename: H
authors.initials: H
authors.lastname: Ueno
authors.forename: T
authors.initials: T
authors.lastname: Kawashima
authors.forename: Y
authors.initials: Y
authors.lastname: Honda
mesh_terms: D000328:Adult; D001281:Atrial Fibrillation / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D001794:Blood Pressure; D002311:Cardiomyopathy, Dilated / Q000150:complications / Q000503:physiopathology; D002312:Cardiomyopathy, Hypertrophic / Q000150:complications* / Q000503:physiopathology; D004206:Disopyramide / Q000627:therapeutic use; D004452:Echocardiography; D004554:Electric Countershock; D005260:Female; D006339:Heart Rate; D006801:Humans; D008297:Male; D008875:Middle Aged; D011802:Quinidine / Q000627:therapeutic use; D016277:Ventricular Function, Left
chemical_list: D004206:Disopyramide; D011802:Quinidine